
Opinion|Videos|May 12, 2025
Applying Trial Data to Real-World Practice in ALK+ NSCLC
Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).
Advertisement
Episodes in this series

Real-World Settings and Evolution of Frontline Therapy
Key Themes:
- Comparison of clinical trial outcomes to real-world patient experiences
- Impact of clinical data (ALINA, CROWN, eXalt3) on frontline therapy choices
- Evolving perspective on frontline therapies for ALK+ NSCLC
Notable Insights:
- Grizzard addressed how well outcomes from trials like CROWN and eXalt3 reflect real-world patient experiences
Dr Dietrich summarized how recent clinical data has changed the landscape of frontline therapies for ALK+ NSCLC
Advertisement
Related to this article

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
4
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
5

